Hyperactive Delirium
9
2
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
11.1%
1 terminated out of 9 trials
66.7%
-19.8% vs benchmark
56%
5 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
Phenobarbital for Agitated Delirium
Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care
HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial
Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium
Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium
Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU
A Pilot Study of "Stanford Proxy Test for Delirium" (S-PTD)
MindfulGarden in Treatment of Hyperactive Delirium in a Hospital Setting
Delirium Prevention in Patients From the Intensive Care Unit (DELA)